» Articles » PMID: 10425403

Structural Organization of Mammalian Lipid Phosphate Phosphatases: Implications for Signal Transduction

Overview
Specialties Biochemistry
Biophysics
Date 1999 Jul 30
PMID 10425403
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

This article describes the regulation of cell signaling by lipid phosphate phosphatases (LPPs) that control the conversion of bioactive lipid phosphates to their dephosphorylated counterparts. A structural model of the LPPs, that were previously called Type 2 phosphatidate phosphatases, is described. LPPs are characterized by having no Mg(2+) requirement and their insensitivity to inhibition by N-ethylmaleimide. The LPPs have six putative transmembrane domains and three highly conserved domains that define a phosphatase superfamily. The conserved domains are juxtaposed to the proposed membrane spanning domains such that they probably form the active sites of the phosphatases. It is predicted that the active sites of the LPPs are exposed at the cell surface or on the luminal surface of intracellular organelles, such as Golgi or the endoplasmic reticulum, depending where various LPPs are expressed. LPPs could attenuate cell activation by dephosphorylating bioactive lipid phosphate esters such as phosphatidate, lysophosphatidate, sphingosine 1-phosphate and ceramide 1-phosphate. In so doing, the LPPs could generate alternative signals from diacylglycerol, sphingosine and ceramide. The LPPs might help to modulate cell signaling by the phospholipase D pathway. For example, phosphatidate generated within the cell by phospholipase D could be converted by an LPP to diacylglycerol. This should change the relative balance of signaling by these two lipids. Another possible function of the LPPs relates to the secretion of lysophosphatidate and sphingosine 1-phosphate by activated platelets and other cells. These exogenous lipids activate phospholipid growth factor receptors on the surface of cells. LPP activities could attenuate cell activation by lysophosphatidate and sphingosine 1-phosphate through their respective receptors.

Citing Articles

Seed-specific expression of phosphatidate phosphohydrolases increases soybean oil content and seed weight.

Chen B, Li J, Yao S, Wang G, Wang X Biotechnol Biofuels Bioprod. 2025; 18(1):23.

PMID: 39994717 PMC: 11849322. DOI: 10.1186/s13068-025-02620-x.


Insights into phosphatidic acid phosphatase and its potential role as a therapeutic target.

Carman G, Stukey G, Jog R, Han G Adv Biol Regul. 2025; 95:101074.

PMID: 39788800 PMC: 11832324. DOI: 10.1016/j.jbior.2025.101074.


The antidepressant drug sertraline is a novel inhibitor of yeast Pah1 and human lipin 1 phosphatidic acid phosphatases.

Stukey G, Breuer M, Burchat N, Jog R, Schultz K, Han G J Lipid Res. 2024; 66(1):100711.

PMID: 39577771 PMC: 11721541. DOI: 10.1016/j.jlr.2024.100711.


Complex sphingolipid profiling and identification of an inositol-phosphorylceramide synthase in .

Listian S, Mazur A, Kol M, Ufelmann E, Eising S, Frohlich F iScience. 2024; 27(9):110609.

PMID: 39286488 PMC: 11402645. DOI: 10.1016/j.isci.2024.110609.


Plasma membrane phospholipid phosphatase-related proteins as pleiotropic regulators of neuron growth and excitability.

Fuchs J, Bareesel S, Kroon C, Polyzou A, Eickholt B, Leondaritis G Front Mol Neurosci. 2022; 15:984655.

PMID: 36187351 PMC: 9520309. DOI: 10.3389/fnmol.2022.984655.